47 related articles for article (PubMed ID: 2731314)
1. Alpha-linolenic acid confers protection on mice renal cells against cisplatin-induced nephrotoxicity.
İstifli ES; Demir E; Kaplan HM; Ateş KE; Doran F
Cytotechnology; 2019 Oct; 71(5):905-914. PubMed ID: 31372877
[TBL] [Abstract][Full Text] [Related]
2. Liquid Chromatography Electrospray Ionization Tandem Mass Spectrometric (LC/ESI-MS/MS) Study for the Identification and Characterization of In Vivo Metabolites of Cisplatin in Rat Kidney Cancer Tissues: Online Hydrogen/Deuterium (H/D) Exchange Study.
Bandu R; Ahn HS; Lee JW; Kim YW; Choi SH; Kim HJ; Kim KP
PLoS One; 2015; 10(8):e0134027. PubMed ID: 26244343
[TBL] [Abstract][Full Text] [Related]
3. Protective effects of
Wang F; Liu S; Shen Y; Zhuang R; Xi J; Fang H; Pan X; Sun J; Cai Z
Exp Ther Med; 2014 Dec; 8(6):1939-1945. PubMed ID: 25371760
[TBL] [Abstract][Full Text] [Related]
4. Sorghum [Sorghum bicolor (L.) Moench] leaf sheath dye protects against cisplatin-induced hepatotoxicity and oxidative stress in rats.
Ademiluyi AO; Oboh G; Agbebi OJ; Boligon AA; Athayde ML
J Med Food; 2014 Dec; 17(12):1332-8. PubMed ID: 25133450
[TBL] [Abstract][Full Text] [Related]
5. Anticancer activity of metal complexes: involvement of redox processes.
Jungwirth U; Kowol CR; Keppler BK; Hartinger CG; Berger W; Heffeter P
Antioxid Redox Signal; 2011 Aug; 15(4):1085-127. PubMed ID: 21275772
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity.
Aleksunes LM; Goedken MJ; Rockwell CE; Thomale J; Manautou JE; Klaassen CD
J Pharmacol Exp Ther; 2010 Oct; 335(1):2-12. PubMed ID: 20605904
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin nephrotoxicity: molecular mechanisms.
Hanigan MH; Devarajan P
Cancer Ther; 2003; 1():47-61. PubMed ID: 18185852
[TBL] [Abstract][Full Text] [Related]
8. High pressure liquid chromatography and mass spectrometry characterization of the nephrotoxic biotransformation products of Cisplatin.
Townsend DM; Marto JA; Deng M; Macdonald TJ; Hanigan MH
Drug Metab Dispos; 2003 Jun; 31(6):705-13. PubMed ID: 12756201
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells.
Townsend DM; Deng M; Zhang L; Lapus MG; Hanigan MH
J Am Soc Nephrol; 2003 Jan; 14(1):1-10. PubMed ID: 12506132
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of gamma-glutamyl transpeptidase or cysteine S-conjugate beta-lyase activity blocks the nephrotoxicity of cisplatin in mice.
Townsend DM; Hanigan MH
J Pharmacol Exp Ther; 2002 Jan; 300(1):142-8. PubMed ID: 11752109
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of cisplatin in proximal and distal renal tubule epithelial cell lines.
Kröning R; Katz D; Lichtenstein AK; Nagami GT
Br J Cancer; 1999 Jan; 79(2):293-9. PubMed ID: 9888471
[TBL] [Abstract][Full Text] [Related]
12. Pressure tuning infrared spectroscopic study of cisplatin-induced structural changes in a phosphatidylserine model membrane.
Taylor KD; Goel R; Shirazi FH; Molepo M; Popovic P; Stewart DJ; Wong PT
Br J Cancer; 1995 Dec; 72(6):1400-5. PubMed ID: 8519651
[TBL] [Abstract][Full Text] [Related]
13. WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.
Treskes M; van der Vijgh WJ
Cancer Chemother Pharmacol; 1993; 33(2):93-106. PubMed ID: 8261581
[TBL] [Abstract][Full Text] [Related]
14. Organ-specific biotransformation of ormaplatin in the Fischer 344 rat.
Thompson DC; Vaisman A; Sakata MK; Wyrick SD; Holbrook DJ; Chaney SG
Cancer Chemother Pharmacol; 1995; 36(5):439-47. PubMed ID: 7634386
[TBL] [Abstract][Full Text] [Related]
15. Preclinical antitumor activity of ethyldeshydroxysparsomycin in combination with cisplatin.
Hofs HP; Wagener DJ; De Valk-Bakker V; Van Rennes H; De Vos D; Doesburg WH; Ottenheijm HC; De Grip WJ
Invest New Drugs; 1995; 13(1):23-32. PubMed ID: 7499104
[TBL] [Abstract][Full Text] [Related]
16. Long-term pharmacokinetic behavior of platinum after cisplatin administration.
Gamelin E; Allain P; Maillart P; Turcant A; Delva R; Lortholary A; Larra F
Cancer Chemother Pharmacol; 1995; 37(1-2):97-102. PubMed ID: 7497604
[TBL] [Abstract][Full Text] [Related]
17. Comparisons of tetrachloro(d,l-trans)1,2-diaminocyclohexane-platinum(IV) biotransformations in the plasma of Fischer 344 rats at therapeutic and toxic doses.
Carfagna PF; Poma A; Wyrick SD; Holbrook DJ; Chaney SG
Cancer Chemother Pharmacol; 1991; 27(5):335-41. PubMed ID: 1998992
[TBL] [Abstract][Full Text] [Related]
18. Intracellular metabolites of cisplatin in the rat kidney.
Mistry P; Lee C; McBrien DC
Cancer Chemother Pharmacol; 1989; 24(2):73-9. PubMed ID: 2731314
[TBL] [Abstract][Full Text] [Related]
19. A study of the protective effect of chloride salts on cisplatin nephrotoxicity.
Daley-Yates PT; McBrien DC
Biochem Pharmacol; 1985 Jul; 34(13):2363-9. PubMed ID: 4040367
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
